Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in co...

Descripción completa

Detalles Bibliográficos
Autores principales: Monks, N R, Calvete, J A, Curtin, N J, Blakey, D C, East, S J, Newell, D R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363482/
https://www.ncbi.nlm.nih.gov/pubmed/10901381
http://dx.doi.org/10.1054/bjoc.2000.1240
_version_ 1782153715909656576
author Monks, N R
Calvete, J A
Curtin, N J
Blakey, D C
East, S J
Newell, D R
author_facet Monks, N R
Calvete, J A
Curtin, N J
Blakey, D C
East, S J
Newell, D R
author_sort Monks, N R
collection PubMed
description ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in colorectal tumour cell-lines. Depletion of intracellular GSH using buthionine sulfoximine (BSO) resulted in only a modest potentiation of ZD2767P + CPG2 activity and hence BSO is unlikely to markedly enhance the activity of this ADEPT treatment. © 2000 Cancer Research Campaign
format Text
id pubmed-2363482
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23634822009-09-10 Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT) Monks, N R Calvete, J A Curtin, N J Blakey, D C East, S J Newell, D R Br J Cancer Regular Article ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in colorectal tumour cell-lines. Depletion of intracellular GSH using buthionine sulfoximine (BSO) resulted in only a modest potentiation of ZD2767P + CPG2 activity and hence BSO is unlikely to markedly enhance the activity of this ADEPT treatment. © 2000 Cancer Research Campaign Nature Publishing Group 2000-07 2000-06-15 /pmc/articles/PMC2363482/ /pubmed/10901381 http://dx.doi.org/10.1054/bjoc.2000.1240 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Monks, N R
Calvete, J A
Curtin, N J
Blakey, D C
East, S J
Newell, D R
Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
title Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
title_full Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
title_fullStr Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
title_full_unstemmed Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
title_short Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
title_sort cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to zd2767 antibody-directed enzyme prodrug therapy (adept)
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363482/
https://www.ncbi.nlm.nih.gov/pubmed/10901381
http://dx.doi.org/10.1054/bjoc.2000.1240
work_keys_str_mv AT monksnr cellularglutathioneasadeterminantofthesensitivityofcolorectaltumourcelllinestozd2767antibodydirectedenzymeprodrugtherapyadept
AT calveteja cellularglutathioneasadeterminantofthesensitivityofcolorectaltumourcelllinestozd2767antibodydirectedenzymeprodrugtherapyadept
AT curtinnj cellularglutathioneasadeterminantofthesensitivityofcolorectaltumourcelllinestozd2767antibodydirectedenzymeprodrugtherapyadept
AT blakeydc cellularglutathioneasadeterminantofthesensitivityofcolorectaltumourcelllinestozd2767antibodydirectedenzymeprodrugtherapyadept
AT eastsj cellularglutathioneasadeterminantofthesensitivityofcolorectaltumourcelllinestozd2767antibodydirectedenzymeprodrugtherapyadept
AT newelldr cellularglutathioneasadeterminantofthesensitivityofcolorectaltumourcelllinestozd2767antibodydirectedenzymeprodrugtherapyadept

Ejemplares similares